Metastatic Renal Cell Carcinoma Clinical Trial
Official title:
Clinical Effectiveness of First-Line Immuno-oncology (IO) Combination Treatment and Subsequent Lines of Therapy in Patients With Metastatic Renal Cell Carcinoma (mRCC) in the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
NCT number | NCT05858749 |
Other study ID # | A4061100 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 20, 2022 |
Est. completion date | November 30, 2022 |
Verified date | May 2023 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to learn about the effectiveness of the first and later lines of medicines on clinical outcomes in people with mRCC. The study includes participants who: - are 18 years old or above and have mRCC - took medicines that use the bodies immunity to fight against cancer as their first choice of treatment - took other medicines after taking the above first choice of treatment This is a study that looks into the data collected through a particular database from selected academic clinical sites participating in this study. The data of interest include: - the length of time between the start of a patient's treatment and the end of treatment - the length of time between the start of treatment and death - physician assessment of a patient's response to treatment We will compare the experiences of people receiving different combinations of treatments and see if there are any differences in the effectiveness of these medicines.
Status | Completed |
Enrollment | 494 |
Est. completion date | November 30, 2022 |
Est. primary completion date | November 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosed with mRCC - Age 18 years or over at the time of mRCC diagnosis - Received IO combination treatment in 1L such as receiving ipilimumab + nivolumab or an axitinib-based regimen (ie, axitinib + pembrolizumab or axitinib + avelumab) as 1L - Received subsequent treatments following 1L (e.g., 2L, 3L) - Actively treated at an IMDC clinical center (to avoid incomplete data) Exclusion Criteria: - There are no exclusion criteria for this study |
Country | Name | City | State |
---|---|---|---|
United States | Pfizer Headquarters | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Demographical characteristics | Gender Age at time of 1L initiation Race Region indicator (i.e., US vs. ex-US) | From Time of Initiation of First-line (1L) Immuno-oncology (IO) combination therapy to death (up to 60 months) | |
Primary | Date of mRCC diagnosis | From Time of Initiation of 1L IO combination therapy to death (up to 60 months) | ||
Primary | Prior nephrectomy status | From Time of Initiation of 1L IO combination therapy to death (up to 60 months) | ||
Primary | Date of nephrectomy (if applicable) | From Time of Initiation of 1L IO combination therapy to death (up to 60 months) | ||
Primary | Tumor characteristics | Histology type (i.e., clear cell vs. non-clear cell RCC) Number of metastatic sites (e.g., 1 site or more than 1 site) Site of metastases (e.g., brain, bone, lung) | From Time of Initiation of 1L IO combination therapy to death (up to 60 months) | |
Primary | IMDC risk score | Assessed on index date and at initiation of each LOT | From Time of Initiation of 1L IO combination therapy to death (up to 60 months) | |
Primary | Number of lines of therapy received by each patient | From Time of Initiation of 1L IO combination therapy to death (up to 60 months) | ||
Primary | Treatment agents received at each line of therapy | From Time of Initiation of 1L IO combination therapy to death (up to 60 months) | ||
Primary | Duration of each line of therapy | From Time of Initiation of 1L IO combination therapy to death (up to 60 months) | ||
Primary | Time from discontinuation of previous line of therapy to initiation of subsequent line of therapy | From Time of Initiation of 1L IO combination therapy to death (up to 60 months) | ||
Primary | Reason for discontinuation for each line of therapy | From Time of Initiation of 1L IO combination therapy to death (up to 60 months) | ||
Primary | Time to treatment discontinuation (TTD) | Defined as the time from treatment initiation to discontinuation of each therapy due to any reason including progression, death, or toxicity | From Time of Initiation of 1L IO combination therapy to death (up to 60 months) | |
Primary | Time to next treatment (TTNT) | Defined as time from the initiation of 1L treatment to initiation of subsequent therapy or death | From Time of Initiation of 1L IO combination therapy to death (up to 60 months) | |
Primary | Physician-assessed best response | Overall best response rate (complete or partial) Stable disease Progressive disease | From Time of Initiation of 1L IO combination therapy to death (up to 60 months) | |
Primary | Overall survival | Defined as the time between initiation of 1L IO combination therapy to death | From Time of Initiation of 1L IO combination therapy to death (up to 60 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00930033 -
Clinical Trial to Assess the Importance of Nephrectomy
|
Phase 3 | |
Recruiting |
NCT05863351 -
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
|
Phase 3 | |
Not yet recruiting |
NCT06284564 -
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
|
Phase 2 | |
Completed |
NCT00414765 -
Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
|
Phase 4 | |
Active, not recruiting |
NCT03149822 -
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03647878 -
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
|
||
Completed |
NCT01517243 -
Phase II Study of Alternating Sunitinib and Temsirolimus
|
Phase 2 | |
Withdrawn |
NCT03927248 -
PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT02122003 -
Second Line Sorafenib After Pazopanib in Patients With RCC
|
Phase 2 | |
Completed |
NCT01182142 -
Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients
|
Phase 2 | |
Completed |
NCT00630409 -
Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
Completed |
NCT04076787 -
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
|
||
Active, not recruiting |
NCT04467021 -
Cancer and Blood Pressure Management, CARISMA Study
|
N/A | |
Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT02282579 -
Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
|
||
Terminated |
NCT02071641 -
Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT01731158 -
Sequential Therapy in Metastatic Renal Cell Carinoma
|
Phase 2 | |
Terminated |
NCT01342627 -
Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT01274273 -
Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
|
Phase 2 |